Pertuzumab in HER2 positive early breast cancer
APHINITY trial
Background: Herceptin or trastuzumab came in as a trailblazer and improved outcomes for patients with HER2 positive breast cancer in all settings. Cancer cells (which are always one step ahead of science) however, have HER1, HER2 , HER 3 and HER4 which are all involved in their propagation. Pertuzumab is a humanized monoclonal antibody that binds to HER…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.